Ambulant treatment of multiple myeloma with combined vincristine, adriamycin and dexamethasone;Ambulante Therapie des multiplen Myeloms mit Vincristin, Adriamycin und Dexamethason

Deutsche Medizinische Wochenschrift

Volumn 122, Issue 17, 1997, Pages 531-535

  Egerer, G ^a   Hegenbart, U ^a   Salwender, H ^a   Hahn, U ^a   Haas, R ^a   Goldschmidt, H ^a   Hunstein, W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CATHETER INFECTION; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA;

EID: 0030983415     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1047649     Document Type: Article

References (23)

1. Alexanian, R., A. Haut, A. U. Kahn, M. Lane, E. M. McKelvey, P. J. Migliore, W. J. Stuckey, H. E. Wilson: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. J. Amer. Med. Ass. 208 (1969), 1680-1685.
2. Attal, M., J.-L. Harousseau, A.-M. Stoppa, J.-J. Sotto, J.-G. Fuzibet, J.-F. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, C. Payen, R. Bataille: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl. J. Med. 335 (1996), 91-97.
3. Barlogie, B., L. Smith, R. Alexanian: Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl. J. Med. 310 (1984), 1353-1356.
4. Beijnen, J. H., C. Neef, O. J. Meuwissen, J. J. Rutten, H. Rosing, W. J. Underberg: Stability of intravenous admixtures of doxorubicin and vincristine. Amer. J. Hosp. Pharm. 43 (1986), 3022-3027.
5. Buzaid, A. C., B. G. M. Durie: Management of refractory myeloma. A review. J. Clin. Oncol. 6 (1988), 889-905.
6. 2-Protocol. Amer. J. Med. 63 (1977), 897-903.
7. Chapel, H. M., M. Lee, R. Hargreaves, D. H. Pamphilon, A. G. Prentice: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma. Lancet 343 (1994), 1059-1063.
8. Cook, G., A. Sahrp, P. Tansey, I. M. Franklin: A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Brit. J. Haematol. 93 (1996), 931-934.
9. Gaj, I., G. P. Sesin: Compatability of doxorubicin hydrochloride and vinblastine sulfate: the stability of a solution stored in cormed reservoir bags or monoject plastic syringes. Amer. J. I. V. Ther. Clin. Nutr. 11 (1984), 8-20.
10. Goldschmidt, H., T. Richter, H. Briedigkeit, W. Schultze, R. Ihle: Komplikationen zentralvenöser Katheter bei Patienten mit hämatologischen Erkrankungen. Z. ärztl. Fortbild. 86 (1992), 37-42.
11. Goldschmidt, H., U. Hegenbart, M. Moos, R. Engenhart, M. Wannenmacher, R. Haas, W. Hunstein: Sequential high-dose teatment with peripheral blood progenitor cell transplantation in patients with multiple myeloma. Stem Cells 13 (1995), Suppl. 3, 36-41.
12. Gore, M. E., C. Viner, M. Meldrum, J. Bell, S. Milan, A. Ziable, M. Slevin et al.: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2 (1989), 879-882.
13. Glasmacher, A., F. Gieseler, M. Gorschlüter, T. Haferlach, R. Kleinschmidt, F. Risse, J. Mezger: Oral idarubicin, vincristine and dexamethason (VID) in the treatment of multiple myeloma. Brit. J. Haematol. 93 (1996), Suppl. 2, 297 (abstract).
14. Hjorth, M., L. Hellquist, E. Holmberg, B. Magnussen, S. Rödjer, J. Westin: Initial treatment in multiple myeloma: no advantage of multi-drug chemotherapy over melphalan-prednisone. Brit. J. Haematol. 74 (1990), 185-191.
15. Maki, D. G., C. E. Weise, H. W. Sarafin: A semi-quantitative culture method for identifying intravenous-catheter-related infection. New Engl. J. Med. 296 (1977), 1305-1310.
16. Monconduit, M., X. Le Loet, J. F. Bernard, J. L. Michaux: Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma. Brit. J. Haematol. 63 (1986), 599-601.
17. Peest, D., H. Deicher, R. Coldewey, R. Leo, H. Bartl, H. J. Bartels, H.J. Braun von Broen, J.T. Fischer, M. Gramatzki, R. Hein, R. Henke, L. Hoffmann, E. D. Kreuser, W. D. Maier, C. R. Meier, J. Oertel, M. Planker, H. M. Reinhold, E. Schäfer, E. Schumacher, K. Schumacher, J. Selbach, M. Stennes, W. Stenzinger, C. Tirier, H. Wagner, H. J. Weh, J. Wysk: Melphalan and prednisone (MP) versus vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAMDex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. Onkologie 13 (1990), 458-460.
18. Samson, D., E. Gaminara, A. Newland, J. Van de Pette, D. McCarty, M. Joyner, L. Aston, T. Mitchell, M. Hamon, A.J. Barret, M. Evans: Infusion of vincristine and doxorubicin with oral dexamethasone as first-line treatment for multiple myeloma. Lancet 2 (1989), 882-886.
19. Samson, D.: Principles of chemotherapy and radiotherapy. In Gahrton and B. Durie (Eds.): Multiple Myeloma (Arnold: London-Sydney-Auckland 1996), 108-129.
20. Schedel, I.: Application of immunoglobulin preparations in multiple myeloma. In Nydegger, U. E., A. Morell (Eds.): Clinical use of intravenous immunoglobulin. (Academic Press: London 1986), 123-132.
21. Sheehan, T., M. Judge, A. C. Parker: The efficacy and toxicity of VAD in the treatment of myeloma and related disorders. Scand. J. Haematol. 37 (1986), 425-428.
22. Simon, C., W. Stille: Therapie von Infektionen bei myeloischer Insuffizienz. In C. Simon und W. Stille (Eds.): Antibiotika-Therapie (Schattauer: Stuttgart-New York 1993), 648-653.
23. Snowdon, L., J. Gibson, L. Johnson, R. Brown, H. Kronenberg: Infection in myeloma patients and correlation with plateau phase. Vth Int. Workshop on Multiple Myeloma, La Baule (1996), 3.89, Abstr.